Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer
“SAN FRANCISCO and SUZHOU, China, Aug. 24, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and commercializing high-quality medicines in oncology, cardiovascular and metabolic diseases, autoimmune, ophthalmology and other major therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a global Phase 3 clinical trial (MarsLight-11) of IBI363 in immunotherapy(IO)-resistant squamous non-small cell lung cancer (NSCLC). IBI363 is Innovent’s self-discovered novel PD-1/IL-2α-bias bispecific antibody fusion protein.”
African American ancestry study identifies lung cancer risk factors
“Despite having lower smoking habits than other groups in the U.S., Black Americans are more likely to develop lung cancer, and their survival rates are significantly worse. What explains this disparity? Scientists at Vanderbilt University Medical Center have analyzed the genetics of their African ancestry in search of risk genes related to the disease and tobacco use. The results reveal new risk factors and confirm the presence of genetic variants that may contribute to the greater impact of lung cancer in this population.”
Atezolizumab Plus Chemo Safe, Efficacious in Broader ES-SCLC Population
“Atezolizumab (Tecentriq) in combination with carboplatin and etoposide demonstrated safety and efficacy findings consistent with what has been seen in previous studies, such as the phase 3 IMpower133 trial (NCT02763579), in an extensive-stage small cell lung cancer (ES-SCLC) patient population similar to the real-world, according to end-of-study results from the phase 3b MAURIS trial (NCT04028050) published in Clinical Lung Cancer.”
New study uncovers potential treatment target for rare lung cancer
“A new study from the University of Oklahoma has provided a new understanding of large cell neuroendocrine carcinoma (LCNEC), a rare and aggressive type of lung cancer. Currently, LCNEC has a high chance of metastasis, no standard treatment and a poor survival rate.”
Efficacy Outcomes Between Tarlatamab and Real-World Physicians’ Choice of Therapies for Previously Treated Extensive Stage Small Cell Lung Cancer
“Conclusion: The study findings suggest that tarlatamab offers potential clinical benefits relative to comparator treatments. This analysis underscores the potential of tarlatamab to become a new therapeutic option for previously treated SCLC, a disease that has historically been associated with extremely poor outcomes and limited treatment options.”
American Lung Association Promotes Biomarker Testing to Improve Lives of People with Lung Cancer
“For people with lung cancer, biomarker testing and targeted therapies can improve treatment outcomes, reduce side effects and help them live longer. Unfortunately, not enough people diagnosed with lung cancer are getting biomarker testing, so the American Lung Association is expanding its Biomarker Education and Awareness for Testing (BEAT) Lung Cancer initiative to increase access to and understanding of biomarker testing, with a particular emphasis on communities bearing the highest lung cancer burden.”
SBI Planning Tool: tackling lung cancer mortality rates in the USA
“The American Cancer Society National Lung Cancer Roundtable (ACS NLCRT), established to bridge different aspects of the healthcare industry, have developed an State-Based Initiatives (SBI) Planning Tool through meetings, interviews and usability testing. This tool provides an easily usable, centralized, web-based approach to reducing lung cancer mortality within the USA by providing personalized recommendations based on a state’s specific needs.”
New Strategy for Small Cell Lung Cancer Treatment Emerges from Dana-Farber Science
“New research from Dana-Farber Cancer Institute shows that a new class of drug results in cancer cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint known as the G1/S checkpoint. The evidence gathered in the Oser Lab at Dana-Farber supports testing of the strategy in humans. A phase 1 clinical trial is now open nationwide for patients with small cell lung cancer, triple negative breast cancer, and other cancers.”
Emotional Distress May Confer Worse Immunotherapy Outcomes in NSCLC
“Pretreatment emotional distress may significantly correlate with worse clinical efficacy following immune checkpoint inhibitor (ICI) use in patients with advanced non–small cell lung cancer (NSCLC), supporting a need for an integrative care approach in this population, according to an editorial commentary published in Translational Lung Cancer Research.”
